search
Back to results

A Trial Evaluating the Effects of a One-year Lifestyle Intervention in Obese Patients With Type 2 Diabetes

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Caloric restriction
Exercise training
Sponsored by
University of Padova
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Obesity, Lifestyle intervention

Eligibility Criteria

30 Years - 64 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Signed informed consent
  • age 30 to 64 years
  • less than 60 min aerobic exercise/week
  • absence of acute diseases
  • no current treatment with insulin or sulfonylureas

Exclusion Criteria:

  • Body mass index (BMI)<28
  • HbA1c<6%
  • Recent acute diseases, severe infections, trauma or surgery
  • Uncontrolled hypertension or hyperglycemia
  • Evidence of advanced cardiovascular, renal or hepatic diseases
  • Contraindication to exercise
  • Body weight change of more than 3% within the last 6 months
  • Medication changes within the last 3 months

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Active Comparator

    Arm Label

    Caloric restriction and early SSET

    Caloric restriction and late SSET

    Arm Description

    Patients will participate to a short lifestyle intervention (LSI), consisting of four weekly group-led lessons lasting 60-90 minutes to educate them on specific dietary and physical activity recommendations for improving health and metabolic control. At the end of the 1-month LSI, participants will start a caloric restriction and early exercise training (SSET) during the first 12-week, followed by no exercise at health centers for 3 months. Between the 6- and the 12-month assessments, participants will continue caloric restriction and will be encouraged to freely exercise.

    Patients will participate to a short lifestyle intervention (LSI), consisting of four weekly group-led lessons lasting 60-90 minutes to educate them on specific dietary and physical activity recommendations for improving health and metabolic control. At the end of the 1-month LSI, participants will start a one-year caloric restriction with no exercise at health centers for 3 months, and then a 12-week exercise training (SSET). Between the 6- and the 12-month assessments, participants will continue caloric restriction and will be encouraged to freely exercise.

    Outcomes

    Primary Outcome Measures

    Change from baseline Glycated Hemoglobin (HbA1c) at 6 months
    Venous blood samples will be collected at morning between 7-9 a.m. for the analysis of Glycated Hemoglobin, performed following standard quality-control procedures.

    Secondary Outcome Measures

    Change from baseline Resting Metabolic Rate at 3 months
    Resting Metabolic Rate will be measured using an open-circuit indirect calorimeter (Sensor Medics VO2max -229 Metabolic System, CA) under standardized procedures
    Change from baseline Resting Metabolic Rate at 6 months
    Resting Metabolic Rate will be measured using an open-circuit indirect calorimeter (Sensor Medics VO2max -229 Metabolic System, CA) under standardized procedures
    Change from baseline Resting Metabolic Rate at 12 months
    Resting Metabolic Rate will be measured using an open-circuit indirect calorimeter (Sensor Medics VO2max -229 Metabolic System, CA) under standardized procedures
    Change from baseline Body mass index at 3 months
    Body weight will be measured to the nearest 0.1 kg and height to the nearest 1 cm using a standard balance and stadiometer (Seca, Germany), with subjects wearing light clothing and no shoes. Body mass index will be computed from the ratio between weight (kg) and height (m) squared.
    Change from baseline Body mass index at 6 months
    Body weight will be measured to the nearest 0.1 kg and height to the nearest 1 cm using a standard balance and stadiometer (Seca, Germany), with subjects wearing light clothing and no shoes. Body mass index will be computed from the ratio between weight (kg) and height (m) squared.
    Change from baseline Body mass index at 12 months
    Body weight will be measured to the nearest 0.1 kg and height to the nearest 1 cm using a standard balance and stadiometer (Seca, Germany), with subjects wearing light clothing and no shoes. Body mass index will be computed from the ratio between weight (kg) and height (m) squared.
    Change from baseline Fat-free mass at 3 months
    Fat-free mass will be estimated by Dual Energy X-ray Absorptiometry, with fan-beam technology (Hologic QDR 4500 W, Inc.).
    Change from baseline Fat-free mass at 6 months
    Fat-free mass will be estimated by Dual Energy X-ray Absorptiometry, with fan-beam technology (Hologic QDR 4500 W, Inc.).
    Change from baseline Fat-free mass at 12 months
    Fat mass will be estimated by Dual Energy X-ray Absorptiometry, with fan-beam technology (Hologic QDR 4500 W, Inc.).
    Change from baseline android to gynoid percent fat ratio at 3 months
    Android to gynoid percent fat ratio will be estimated by Dual Energy X-ray Absorptiometry, with fan-beam technology (Hologic QDR 4500 W, Inc.).
    Change from baseline android to gynoid percent fat ratio at 6 months
    Android to gynoid percent fat ratio will be estimated by Dual Energy X-ray Absorptiometry, with fan-beam technology (Hologic QDR 4500 W, Inc.).
    Change from baseline android to gynoid percent fat ratio at 12 months
    Android to gynoid percent fat ratio will be estimated by Dual Energy X-ray Absorptiometry, with fan-beam technology (Hologic QDR 4500 W, Inc.).
    Change from baseline fasting plasma glucose at 3 months
    Venous blood samples will be collected in the morning between 7-9 a.m. after 12 hours of fasting and plasma glucose will be assessed following standard quality-control procedures.
    Change from baseline fasting plasma glucose at 6 months
    Venous blood samples will be collected in the morning between 7-9 a.m. after 12 hours of fasting and plasma glucose will be assessed following standard quality-control procedures.
    Change from baseline fasting plasma glucose at 12 months
    Venous blood samples will be collected in the morning between 7-9 a.m. after 12 hours of fasting and plasma glucose will be assessed following standard quality-control procedures.
    Change from baseline HDL cholesterol at 3 months
    Venous blood samples will be collected in the morning between 7-9 a.m. after 12 hours of fasting and HDL cholesterol will be assessed following standard quality-control procedures.
    Change from baseline HDL cholesterol at 6 months
    Venous blood samples will be collected in the morning between 7-9 a.m. after 12 hours of fasting and HDL cholesterol will be assessed following standard quality-control procedures.
    Change from baseline HDL cholesterol at 12 months
    Venous blood samples will be collected in the morning between 7-9 a.m. after 12 hours of fasting and HDL cholesterol will be assessed following standard quality-control procedures.
    Change from baseline total cholesterol at 3 months
    Venous blood samples will be collected in the morning between 7-9 a.m. after 12 hours of fasting and total cholesterol levels will be assessed following standard quality-control procedures.
    Change from baseline total cholesterol at 6 months
    Venous blood samples will be collected in the morning between 7-9 a.m. after 12 hours of fasting and total cholesterol levels will be assessed following standard quality-control procedures.
    Change from baseline total cholesterol at 12 months
    Venous blood samples will be collected in the morning between 7-9 a.m. after 12 hours of fasting and total cholesterol levels will be assessed following standard quality-control procedures.
    Change from baseline triglycerides levels at 3 months
    Venous blood samples will be collected in the morning between 7-9 a.m. after 12 hours of fasting and plasma triglycerides levels will be assessed following standard quality-control procedures.
    Change from baseline triglycerides levels at 6 months
    Venous blood samples will be collected in the morning between 7-9 a.m. after 12 hours of fasting and plasma triglycerides levels will be assessed following standard quality-control procedures.
    Change from baseline triglycerides levels at 12 months
    Venous blood samples will be collected in the morning between 7-9 a.m. after 12 hours of fasting and plasma triglycerides levels will be assessed following standard quality-control procedures.
    Change from baseline serum creatinine at 3 months
    Serum creatinine will be assessed from venous blood samples following standard quality-control procedures.
    Change from baseline serum creatinine at 6 months
    Serum creatinine will be assessed from venous blood samples following standard quality-control procedures.
    Change from baseline serum creatinine at 12 months
    Serum creatinine will be assessed from venous blood samples following standard quality-control procedures.
    Change from baseline urinary albumin-to-creatinine ratio at 3 months
    Urine samples will be collected for the assessment of urinary albumin-to-creatinine ratio (ACR) following standard quality-control procedures.
    Change from baseline urinary albumin-to-creatinine ratio at 6 months
    Urine samples will be collected for the assessment of urinary albumin-to-creatinine ratio (ACR) following standard quality-control procedures.
    Change from baseline urinary albumin-to-creatinine ratio at 12 months
    Urine samples will be collected for the assessment of urinary albumin-to-creatinine ratio (ACR) following standard quality-control procedures.
    Change from baseline maximal aerobic power at 3 months
    VO2max will be measured by the Sensor Medics VO2max -229 Metabolic System using a continuous incremental treadmill protocol (Runner MTC Climb, Italy) according to the modified Naughton protocol.
    Change from baseline maximal aerobic power at 6 months
    VO2max will be measured by the Sensor Medics VO2max -229 Metabolic System using a continuous incremental treadmill protocol (Runner MTC Climb, Italy) according to the modified Naughton protocol.
    Change from baseline maximal aerobic power at 12 months
    VO2max will be measured by the Sensor Medics VO2max -229 Metabolic System using a continuous incremental treadmill protocol (Runner MTC Climb, Italy) according to the modified Naughton protocol.
    Change from baseline Glycated Hemoglobin (HbA1c) at 3 months
    Venous blood samples will be collected at morning between 7-9 a.m. for the analysis of Glycated Hemoglobin, performed following standard quality-control procedures.
    Change from baseline Glycated Hemoglobin (HbA1c) at 12 months
    Venous blood samples will be collected at morning between 7-9 a.m. for the analysis of Glycated Hemoglobin, performed following standard quality-control procedures.

    Full Information

    First Posted
    October 26, 2018
    Last Updated
    December 21, 2018
    Sponsor
    University of Padova
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03785379
    Brief Title
    A Trial Evaluating the Effects of a One-year Lifestyle Intervention in Obese Patients With Type 2 Diabetes
    Official Title
    A Randomized Trial Evaluating the Effects of One-Year Caloric Restriction and 12-Week Exercise Training Intervention in Obese Adults With Type 2 Diabetes: Emphasis on Metabolic Control and Resting Metabolic Rate
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    December 2018
    Overall Recruitment Status
    Completed
    Study Start Date
    February 2013 (Actual)
    Primary Completion Date
    October 2015 (Actual)
    Study Completion Date
    October 2015 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    University of Padova

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    Diabetic patients with uncontrolled disease are often characterized by increased energy expenditure and could thus present a high resting metabolic rate (RMR). Lifestyle interventions aimed at improving glucose control in these patients may lead to reductions of futile pathways, resulting in lower rates of energy expenditure, and paradoxically to making it more difficult to lose weight. However, only few studies investigated how exercise could influence patients' RMR and results are still not unanimous. In this study, we aim to investigate the effects on metabolic health of a combined dietary intervention and 12-week exercise training in obese adults with type 2 diabetes.
    Detailed Description
    Although a number of exercise training interventions have been proposed to type 2 diabetes patients, the current clinical practice demonstrates that most patients are still sedentary and with excess body weight. A negative balance between energy intake and energy expenditure is crucial to reduce excess body weight. However, diabetic patients with uncontrolled disease are often characterized by increased energy expenditure and could thus present a high resting metabolic rate (RMR). Lifestyle interventions aimed at improving glucose control in these patients may lead to reductions of futile pathways, resulting in lower rates of energy expenditure, and paradoxically to making it more difficult to lose weight. However, no robust evidence has been collected on this issue, and the few studies that investigated how exercise could influence patients' RMR have not shown unanimous results, especially concerning combined dietary and physical activity interventions. This open-label randomized trial in obese adults with type 2 diabetes aims to investigate the effects of a 1-year caloric restriction and 12-week exercise training intervention on metabolic health, RMR and VO2max. In particular, eligible type 2 diabetes patients of our clinic will be invited to participate in a short lifestyle intervention (LSI). LSI will consist of four weekly group-led lessons lasting 60-90 minutes in which specialized professionals will educate patients on specific dietary and physical activity recommendations for improving health and metabolic control. After this month, patients will be randomly assigned either to: 1) 1-year caloric restriction with an immediate start of 12-week supervised structured exercise training (SSET) (Early-SSET intervention), followed by no exercise at health centers for 3 months; or: 2) 1-year caloric restriction with no exercise at health centers for 3 months and then a 12-week SSET from month 4 to month 6 (Late-SSET intervention). During the last 6 months participants' activity will be unrestricted. Type 2 diabetic and obese adult volunteers will be recruited and screened through medical history, physical examination and biochemical analyses.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Type 2 Diabetes Mellitus
    Keywords
    Obesity, Lifestyle intervention

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    After the baseline assessment, patients will be randomly assigned either to: 1) 1-year caloric restriction with an immediate start of 12-week supervised structured exercise training (SSET) (Early-SSET intervention), followed by no exercise at health centers for 3 months; or: 2) 1-year caloric restriction with no exercise at health centers for 3 months and then a 12-week SSET from month 4 to month 6 (Late-SSET intervention). During the last 6 months participants' activity will be unrestricted.
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    23 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Caloric restriction and early SSET
    Arm Type
    Active Comparator
    Arm Description
    Patients will participate to a short lifestyle intervention (LSI), consisting of four weekly group-led lessons lasting 60-90 minutes to educate them on specific dietary and physical activity recommendations for improving health and metabolic control. At the end of the 1-month LSI, participants will start a caloric restriction and early exercise training (SSET) during the first 12-week, followed by no exercise at health centers for 3 months. Between the 6- and the 12-month assessments, participants will continue caloric restriction and will be encouraged to freely exercise.
    Arm Title
    Caloric restriction and late SSET
    Arm Type
    Active Comparator
    Arm Description
    Patients will participate to a short lifestyle intervention (LSI), consisting of four weekly group-led lessons lasting 60-90 minutes to educate them on specific dietary and physical activity recommendations for improving health and metabolic control. At the end of the 1-month LSI, participants will start a one-year caloric restriction with no exercise at health centers for 3 months, and then a 12-week exercise training (SSET). Between the 6- and the 12-month assessments, participants will continue caloric restriction and will be encouraged to freely exercise.
    Intervention Type
    Behavioral
    Intervention Name(s)
    Caloric restriction
    Other Intervention Name(s)
    One-year caloric restriction
    Intervention Description
    A structured dietary training will be implemented to educate participants about recommended dietary habits.Patients will follow a caloric restriction (CR) diet, with an energy intake equal to the measured Resting Metabolic Rate (RMR) and with 45% carbohydrate, 20%protein, 35%fat, and 30 g/day fibers. At each follow-up, nutritionist will adjust CR to the latest measured RMR and assess the compliance to the diet.
    Intervention Type
    Behavioral
    Intervention Name(s)
    Exercise training
    Other Intervention Name(s)
    12-week structured supervised exercise training (SSET)
    Intervention Description
    Trainers will supervise participants during 12-weeks of structured exercise consisting of 150 min/week workouts, divided in three sessions of progressive mixed (aerobic and resistance) exercise. All aerobic exercise will be performed using treadmill and/or cycle ergo-meter.
    Primary Outcome Measure Information:
    Title
    Change from baseline Glycated Hemoglobin (HbA1c) at 6 months
    Description
    Venous blood samples will be collected at morning between 7-9 a.m. for the analysis of Glycated Hemoglobin, performed following standard quality-control procedures.
    Time Frame
    6 months
    Secondary Outcome Measure Information:
    Title
    Change from baseline Resting Metabolic Rate at 3 months
    Description
    Resting Metabolic Rate will be measured using an open-circuit indirect calorimeter (Sensor Medics VO2max -229 Metabolic System, CA) under standardized procedures
    Time Frame
    3 months
    Title
    Change from baseline Resting Metabolic Rate at 6 months
    Description
    Resting Metabolic Rate will be measured using an open-circuit indirect calorimeter (Sensor Medics VO2max -229 Metabolic System, CA) under standardized procedures
    Time Frame
    6 months
    Title
    Change from baseline Resting Metabolic Rate at 12 months
    Description
    Resting Metabolic Rate will be measured using an open-circuit indirect calorimeter (Sensor Medics VO2max -229 Metabolic System, CA) under standardized procedures
    Time Frame
    12 months
    Title
    Change from baseline Body mass index at 3 months
    Description
    Body weight will be measured to the nearest 0.1 kg and height to the nearest 1 cm using a standard balance and stadiometer (Seca, Germany), with subjects wearing light clothing and no shoes. Body mass index will be computed from the ratio between weight (kg) and height (m) squared.
    Time Frame
    3 months
    Title
    Change from baseline Body mass index at 6 months
    Description
    Body weight will be measured to the nearest 0.1 kg and height to the nearest 1 cm using a standard balance and stadiometer (Seca, Germany), with subjects wearing light clothing and no shoes. Body mass index will be computed from the ratio between weight (kg) and height (m) squared.
    Time Frame
    6 months
    Title
    Change from baseline Body mass index at 12 months
    Description
    Body weight will be measured to the nearest 0.1 kg and height to the nearest 1 cm using a standard balance and stadiometer (Seca, Germany), with subjects wearing light clothing and no shoes. Body mass index will be computed from the ratio between weight (kg) and height (m) squared.
    Time Frame
    12 months
    Title
    Change from baseline Fat-free mass at 3 months
    Description
    Fat-free mass will be estimated by Dual Energy X-ray Absorptiometry, with fan-beam technology (Hologic QDR 4500 W, Inc.).
    Time Frame
    3 months
    Title
    Change from baseline Fat-free mass at 6 months
    Description
    Fat-free mass will be estimated by Dual Energy X-ray Absorptiometry, with fan-beam technology (Hologic QDR 4500 W, Inc.).
    Time Frame
    6 months
    Title
    Change from baseline Fat-free mass at 12 months
    Description
    Fat mass will be estimated by Dual Energy X-ray Absorptiometry, with fan-beam technology (Hologic QDR 4500 W, Inc.).
    Time Frame
    12 months
    Title
    Change from baseline android to gynoid percent fat ratio at 3 months
    Description
    Android to gynoid percent fat ratio will be estimated by Dual Energy X-ray Absorptiometry, with fan-beam technology (Hologic QDR 4500 W, Inc.).
    Time Frame
    3 months
    Title
    Change from baseline android to gynoid percent fat ratio at 6 months
    Description
    Android to gynoid percent fat ratio will be estimated by Dual Energy X-ray Absorptiometry, with fan-beam technology (Hologic QDR 4500 W, Inc.).
    Time Frame
    6 months
    Title
    Change from baseline android to gynoid percent fat ratio at 12 months
    Description
    Android to gynoid percent fat ratio will be estimated by Dual Energy X-ray Absorptiometry, with fan-beam technology (Hologic QDR 4500 W, Inc.).
    Time Frame
    12 months
    Title
    Change from baseline fasting plasma glucose at 3 months
    Description
    Venous blood samples will be collected in the morning between 7-9 a.m. after 12 hours of fasting and plasma glucose will be assessed following standard quality-control procedures.
    Time Frame
    3 months
    Title
    Change from baseline fasting plasma glucose at 6 months
    Description
    Venous blood samples will be collected in the morning between 7-9 a.m. after 12 hours of fasting and plasma glucose will be assessed following standard quality-control procedures.
    Time Frame
    6 months
    Title
    Change from baseline fasting plasma glucose at 12 months
    Description
    Venous blood samples will be collected in the morning between 7-9 a.m. after 12 hours of fasting and plasma glucose will be assessed following standard quality-control procedures.
    Time Frame
    12 months
    Title
    Change from baseline HDL cholesterol at 3 months
    Description
    Venous blood samples will be collected in the morning between 7-9 a.m. after 12 hours of fasting and HDL cholesterol will be assessed following standard quality-control procedures.
    Time Frame
    3 months
    Title
    Change from baseline HDL cholesterol at 6 months
    Description
    Venous blood samples will be collected in the morning between 7-9 a.m. after 12 hours of fasting and HDL cholesterol will be assessed following standard quality-control procedures.
    Time Frame
    6 months
    Title
    Change from baseline HDL cholesterol at 12 months
    Description
    Venous blood samples will be collected in the morning between 7-9 a.m. after 12 hours of fasting and HDL cholesterol will be assessed following standard quality-control procedures.
    Time Frame
    12 months
    Title
    Change from baseline total cholesterol at 3 months
    Description
    Venous blood samples will be collected in the morning between 7-9 a.m. after 12 hours of fasting and total cholesterol levels will be assessed following standard quality-control procedures.
    Time Frame
    3 months
    Title
    Change from baseline total cholesterol at 6 months
    Description
    Venous blood samples will be collected in the morning between 7-9 a.m. after 12 hours of fasting and total cholesterol levels will be assessed following standard quality-control procedures.
    Time Frame
    6 months
    Title
    Change from baseline total cholesterol at 12 months
    Description
    Venous blood samples will be collected in the morning between 7-9 a.m. after 12 hours of fasting and total cholesterol levels will be assessed following standard quality-control procedures.
    Time Frame
    12 months
    Title
    Change from baseline triglycerides levels at 3 months
    Description
    Venous blood samples will be collected in the morning between 7-9 a.m. after 12 hours of fasting and plasma triglycerides levels will be assessed following standard quality-control procedures.
    Time Frame
    3 months
    Title
    Change from baseline triglycerides levels at 6 months
    Description
    Venous blood samples will be collected in the morning between 7-9 a.m. after 12 hours of fasting and plasma triglycerides levels will be assessed following standard quality-control procedures.
    Time Frame
    6 months
    Title
    Change from baseline triglycerides levels at 12 months
    Description
    Venous blood samples will be collected in the morning between 7-9 a.m. after 12 hours of fasting and plasma triglycerides levels will be assessed following standard quality-control procedures.
    Time Frame
    12 months
    Title
    Change from baseline serum creatinine at 3 months
    Description
    Serum creatinine will be assessed from venous blood samples following standard quality-control procedures.
    Time Frame
    3 months
    Title
    Change from baseline serum creatinine at 6 months
    Description
    Serum creatinine will be assessed from venous blood samples following standard quality-control procedures.
    Time Frame
    6 months
    Title
    Change from baseline serum creatinine at 12 months
    Description
    Serum creatinine will be assessed from venous blood samples following standard quality-control procedures.
    Time Frame
    12 months
    Title
    Change from baseline urinary albumin-to-creatinine ratio at 3 months
    Description
    Urine samples will be collected for the assessment of urinary albumin-to-creatinine ratio (ACR) following standard quality-control procedures.
    Time Frame
    3 months
    Title
    Change from baseline urinary albumin-to-creatinine ratio at 6 months
    Description
    Urine samples will be collected for the assessment of urinary albumin-to-creatinine ratio (ACR) following standard quality-control procedures.
    Time Frame
    6 months
    Title
    Change from baseline urinary albumin-to-creatinine ratio at 12 months
    Description
    Urine samples will be collected for the assessment of urinary albumin-to-creatinine ratio (ACR) following standard quality-control procedures.
    Time Frame
    12 months
    Title
    Change from baseline maximal aerobic power at 3 months
    Description
    VO2max will be measured by the Sensor Medics VO2max -229 Metabolic System using a continuous incremental treadmill protocol (Runner MTC Climb, Italy) according to the modified Naughton protocol.
    Time Frame
    3 months
    Title
    Change from baseline maximal aerobic power at 6 months
    Description
    VO2max will be measured by the Sensor Medics VO2max -229 Metabolic System using a continuous incremental treadmill protocol (Runner MTC Climb, Italy) according to the modified Naughton protocol.
    Time Frame
    6 months
    Title
    Change from baseline maximal aerobic power at 12 months
    Description
    VO2max will be measured by the Sensor Medics VO2max -229 Metabolic System using a continuous incremental treadmill protocol (Runner MTC Climb, Italy) according to the modified Naughton protocol.
    Time Frame
    12 months
    Title
    Change from baseline Glycated Hemoglobin (HbA1c) at 3 months
    Description
    Venous blood samples will be collected at morning between 7-9 a.m. for the analysis of Glycated Hemoglobin, performed following standard quality-control procedures.
    Time Frame
    3 months
    Title
    Change from baseline Glycated Hemoglobin (HbA1c) at 12 months
    Description
    Venous blood samples will be collected at morning between 7-9 a.m. for the analysis of Glycated Hemoglobin, performed following standard quality-control procedures.
    Time Frame
    12 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    30 Years
    Maximum Age & Unit of Time
    64 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Signed informed consent age 30 to 64 years less than 60 min aerobic exercise/week absence of acute diseases no current treatment with insulin or sulfonylureas Exclusion Criteria: Body mass index (BMI)<28 HbA1c<6% Recent acute diseases, severe infections, trauma or surgery Uncontrolled hypertension or hyperglycemia Evidence of advanced cardiovascular, renal or hepatic diseases Contraindication to exercise Body weight change of more than 3% within the last 6 months Medication changes within the last 3 months
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Francesco Zurlo, MD
    Organizational Affiliation
    University of Padova
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    24070224
    Citation
    Alawad AO, Merghani TH, Ballal MA. Resting metabolic rate in obese diabetic and obese non-diabetic subjects and its relation to glycaemic control. BMC Res Notes. 2013 Sep 26;6:382. doi: 10.1186/1756-0500-6-382.
    Results Reference
    background
    PubMed Identifier
    6337503
    Citation
    Stevenson RW, Parsons JA, Alberti KG. Effect of intraportal and peripheral insulin on glucose turnover and recycling in diabetic dogs. Am J Physiol. 1983 Feb;244(2):E190-5. doi: 10.1152/ajpendo.1983.244.2.E190.
    Results Reference
    background
    PubMed Identifier
    3391340
    Citation
    Zawadzki JK, Wolfe RR, Mott DM, Lillioja S, Howard BV, Bogardus C. Increased rate of Cori cycle in obese subjects with NIDDM and effect of weight reduction. Diabetes. 1988 Feb;37(2):154-9. doi: 10.2337/diab.37.2.154.
    Results Reference
    background
    PubMed Identifier
    25559400
    Citation
    Piaggi P, Thearle MS, Bogardus C, Krakoff J. Fasting hyperglycemia predicts lower rates of weight gain by increased energy expenditure and fat oxidation rate. J Clin Endocrinol Metab. 2015 Mar;100(3):1078-87. doi: 10.1210/jc.2014-3582. Epub 2015 Jan 5.
    Results Reference
    background
    PubMed Identifier
    16979410
    Citation
    Araiza P, Hewes H, Gashetewa C, Vella CA, Burge MR. Efficacy of a pedometer-based physical activity program on parameters of diabetes control in type 2 diabetes mellitus. Metabolism. 2006 Oct;55(10):1382-7. doi: 10.1016/j.metabol.2006.06.009.
    Results Reference
    background
    PubMed Identifier
    19568205
    Citation
    Jennings AE, Alberga A, Sigal RJ, Jay O, Boule NG, Kenny GP. The effect of exercise training on resting metabolic rate in type 2 diabetes mellitus. Med Sci Sports Exerc. 2009 Aug;41(8):1558-65. doi: 10.1249/MSS.0b013e31819d6a6f.
    Results Reference
    background
    PubMed Identifier
    9051392
    Citation
    Mourier A, Gautier JF, De Kerviler E, Bigard AX, Villette JM, Garnier JP, Duvallet A, Guezennec CY, Cathelineau G. Mobilization of visceral adipose tissue related to the improvement in insulin sensitivity in response to physical training in NIDDM. Effects of branched-chain amino acid supplements. Diabetes Care. 1997 Mar;20(3):385-91. doi: 10.2337/diacare.20.3.385.
    Results Reference
    background
    PubMed Identifier
    28659869
    Citation
    Karstoft K, Brinklov CF, Thorsen IK, Nielsen JS, Ried-Larsen M. Resting Metabolic Rate Does Not Change in Response to Different Types of Training in Subjects with Type 2 Diabetes. Front Endocrinol (Lausanne). 2017 Jun 13;8:132. doi: 10.3389/fendo.2017.00132. eCollection 2017.
    Results Reference
    background
    PubMed Identifier
    31359403
    Citation
    Zurlo F, Trevisan C, Vitturi N, Ravussin E, Salvo C, Carraro S, Siffi M, Iob I, Saller A, Previato L, Sergi G, de Kreutzenberg S, Maran A, Avogaro A. One-year caloric restriction and 12-week exercise training intervention in obese adults with type 2 diabetes: emphasis on metabolic control and resting metabolic rate. J Endocrinol Invest. 2019 Dec;42(12):1497-1507. doi: 10.1007/s40618-019-01090-x. Epub 2019 Jul 29.
    Results Reference
    derived

    Learn more about this trial

    A Trial Evaluating the Effects of a One-year Lifestyle Intervention in Obese Patients With Type 2 Diabetes

    We'll reach out to this number within 24 hrs